Serious Infections Caused by Methicillin‐ResistantStaphylococcus aureus
Citations Over TimeTop 10% of 2010 papers
Abstract
Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.
Related Papers
- → Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin(2021)5 cited
- → Комбинированная терапия как путь к предотвращению антибиотикорезистентности бактерий: линезолид—даптомицин против Staphylococcus aureus(2019)2 cited
- [Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against gram-positive bacteria].(1989)
- → Oritavancin activity tested against European staphylococcal clinical isolates and resistant subsets including those with reduced susceptibility to daptomycin, teicoplanin or vancomycin (2010 – 2014)(2016)